Ikena Oncology Inc. (NASDAQ: IKNA)
$1.72
+0.0200 ( +1.18% ) 83.9K
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Market Data
Open
$1.72
Previous close
$1.70
Volume
83.9K
Market cap
$83.25M
Day range
$1.70 - $1.76
52 week range
$1.02 - $6.80
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jul 12, 2024 |
8-k | 8K-related | 13 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
8-k | 8K-related | 36 | May 28, 2024 |